Curis to Present at Merriman Curhan Ford`s Investor Summit 2009

CAMBRIDGE, Mass.--(Business Wire)--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next
generation targeted small molecule drug candidates for cancer treatment, today
announced that the Company will be presenting at Merriman Curhan Ford`s Investor
Summit at 9:00 a.m. EST on November 10, 2009, in New York City.

Dan Passeri, Curis` President and Chief Executive Officer, will provide an
overview of the status of GDC-0449, an orally-administered small molecule
Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in Phase II
clinical trials by Curis` collaborator Genentech, including in a pivotal Phase
II trial in advanced basal cell carcinoma and Phase II trials in metastatic
colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss
CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to
other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed
by visiting:

http://www.wsw.com/webcast/mcm12/cris/

The presentation will be archived shortly after the live event and available for
30 days following the conference. In addition, it will be available for 30 days
on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its
innovative signaling pathway drug technologies to seek to create new targeted
small molecule drug candidates for cancer. In expanding its drug development
efforts in the field of cancer through its proprietary targeted cancer programs,
Curis is building upon its previous experiences in targeting signaling pathways
for the development of next generation targeted cancer therapies. For more
information, visit Curis' website at www.curis.com.

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com

Copyright Business Wire 2009